“The select trial, led by University College London (UCL), looked at whether or not people taking the drug went on to suffer a ‘major adverse cardiac event’ – including heart disease deaths, heart attacks or strokes.

They examined data on 17,604 people aged 45 and over who were either overweight or obese.

Half of the people taking part in the study – which took place across 41 countries – were given weekly injections of semaglutide. The other half were given a dummy drug, known as a placebo.

Previous analysis of the data found that semaglutide reduced the risk of major adverse cardiac events by 20%. Researchers have now found the benefit was apparent regardless of how much weight people lost while taking the drug.”

From The Guardian.